Literature DB >> 25439431

Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control.

Arman Mashayekhi1, Carol L Shields2, Pukhraj Rishi2, Hatice T Atalay2, Marco Pellegrini2, John P McLaughlin2, Kaitlin A Patrick2, Spenser J Morton2, Meredith H Remmer2, Anthony Parendo2, Meghan A Schlitt2, Jerry A Shields2.   

Abstract

PURPOSE: To report the long-term outcome of primary transpupillary thermotherapy (TTT) for choroidal melanoma.
DESIGN: Retrospective review of medical records. PARTICIPANTS: We included 391 patients with choroidal melanoma treated between 1995 and 2012 at the Oncology Service, Wills Eye Hospital, Philadelphia.
METHODS: We delivered TTT with an infrared diode laser. MAIN OUTCOME MEASURES: Local tumor recurrence, Snellen visual acuity after TTT, and distant metastasis.
RESULTS: Of 391 patients, 311 (80%) were treated from 1995 to 2000 and 80 (20%) from 2001 to 2012. Tumors in the 2001 to 2012 group were ultrasonographically thinner (2.2 vs. 2.7 mm), more distant from the optic disc (3.2 vs. 2.5 mm) and foveola (4.0 vs. 2.0 mm), were less often located in the macular area (14% vs. 40%), and had lower rates of acoustic hollowness on B-scan ultrasonography (63% vs. 84%), subretinal fluid (58% vs. 90%), and orange pigment (50% vs. 70%). Kaplan-Meier estimates for tumor recurrence in the 1995 to 2000 group were 29% at 5 years and 42% at 10 years, whereas estimates for tumor recurrence in the 2001-2012 group were 11% at 5 years and 15% at 10 years. Of 108 recurrent tumors 20 were controlled with additional TTT and 62 required plaque radiation (n=60) or proton beam radiation (n=2), with enucleation necessary in 26 patients. Tumor recurrence correlated with the number of high-risk tumor features: 10-year recurrence was 18% in those with 1 or 2 risk factors, 35% in those with 3 to 5 factors, and 55% in those with 6 or 7 factors. On multivariate analysis, features predictive of tumor recurrence were presence of symptoms (P<0.001), shorter distance between the tumor and the optic disc (P=0.026), subretinal fluid (P=0.035), thickness of residual tumor scar (P<0.001), and elevation of residual tumor scar (P<0.001). The only factor predictive of extraocular tumor extension was intraocular tumor recurrence after TTT treated with additional TTT (P=0.007). Presence of orange pigment before TTT (P=0.019), tumor recurrence (P=0.002), and extraocular tumor extension (P=0.017) were predictive of distant metastasis.
CONCLUSION: This study shows a direct correlation between a larger number of high-risk tumor features and higher rates of tumor recurrence after primary TTT of (small) choroidal melanoma. We advise that, when possible, small choroidal melanomas with multiple risk factors be treated with methods other than TTT.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25439431     DOI: 10.1016/j.ophtha.2014.09.029

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

Review 1.  Low-dose brachytherapy strategies to treat uveal melanoma: is less more?

Authors:  Patrick Oellers; Prithvi Mruthyunjaya
Journal:  Melanoma Manag       Date:  2016-02-17

Review 2.  Uveal melanoma: relatively rare but deadly cancer.

Authors:  S Kaliki; C L Shields
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775

3.  Secondary endoresection for previously treated choroidal melanomas with a non-responsive course and persistent exudative retinal detachment.

Authors:  Ahmet Kaan Gündüz; Ibadulla Mirzayev
Journal:  Int J Ophthalmol       Date:  2022-02-18       Impact factor: 1.779

Review 4.  Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications.

Authors:  Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Rocco Luca Emanuele Liardo; Roberto Milazzotto; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile
Journal:  Insights Imaging       Date:  2021-06-04

Review 5.  Uveal Melanoma: Current Trends in Diagnosis and Management.

Authors:  Berçin Tarlan; Hayyam Kıratlı
Journal:  Turk J Ophthalmol       Date:  2016-06-06

6.  Ruthenium-106 Brachytherapy with or without Additional Local Therapy Shows Favorable Outcome for Variable-Sized Choroidal Melanomas in Korean Patients.

Authors:  Yeona Cho; Jee Suk Chang; Jin Sook Yoon; Sung Chul Lee; Yong Bae Kim; Joo Ho Kim; Ki Chang Keum
Journal:  Cancer Res Treat       Date:  2017-03-24       Impact factor: 4.679

Review 7.  Uveal melanoma: epidemiology, etiology, and treatment of primary disease.

Authors:  Benjamin A Krantz; Nikita Dave; Kimberly M Komatsubara; Brian P Marr; Richard D Carvajal
Journal:  Clin Ophthalmol       Date:  2017-01-31

8.  Small High-Risk Uveal Melanomas Have a Lower Mortality Rate.

Authors:  Rumana N Hussain; Sarah E Coupland; Helen Kalirai; Azzam F G Taktak; Antonio Eleuteri; Bertil E Damato; Carl Groenewald; Heinrich Heimann
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

Review 9.  Choroidal melanoma: A short review with an Indian perspective.

Authors:  Bikramjit P Pal; Saili Garge; Vikas Khetan
Journal:  Oman J Ophthalmol       Date:  2017 Sep-Dec

10.  Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis.

Authors:  Yuan James Rao; Julia Sein; Shahed Badiyan; Julie K Schwarz; Todd DeWees; Perry Grigsby; Prabakar Kumar Rao
Journal:  J Contemp Brachytherapy       Date:  2017-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.